At a glance
ClinicalIndex Comparison RecordPhase 2Not Yet Recruiting· 40 target
Drug / intervention
PM8002 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Multicenter, Open Label, Parallel Cohort Clinical Trial to Evaluate the Efficacy and Safety of PM8002 (BNT327) in Combination With Chemotherapy in First Line MSS or MSI-L/pMMR Metastatic Colorectal Cancer
In Brief
A Phase 2 clinical trial evaluating PM8002, Chemotherapy Regimen 1, and 1 other intervention for CRC (Colorectal Cancer). Not yet recruiting, targeting 40 participants across 1 site.
Detailed Summary
PM8002 (BNT327) is a bispecific antibody targeting PD-L1 and VEGF. This is a phase II trial to evaluate the efficacy and safety of PM8002 in combination with chemotherapy in first line MSS or MSI-L/pMMR metastatic colorectal cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCRC (Colorectal Cancer)
CountriesChina
CollaboratorsBioNTech SE
Timeline
Phase 2Not Yet Recruiting
2026202720282029
Enrollment StartAug 2025
First PostedAug 2025
TodayJul 2026
Primary CompletionAug 2026
Study CompletionAug 2029
First PostedAug 21, 2025
Enrollment StartAug 1, 2025
Primary CompletionAug 1, 2026
Study CompletionAug 1, 2029
TodayJul 1, 2026
Enrollment to primary: 1 yearPosted 10 months agoPrimary completion in 1 month
Interventions
PM8002drug
IV infusion
Chemotherapy Regimen 1drug
IV infusion
Chemotherapy Regimen 2drug
Oral administration and IV infusion